another example of the failed “Single Target” paradigm, which is argued to be the underlying cause of the productivity crisis in pharmaceutical R&D. This paradigm is explained in a paper published on March, 2012 in the medical journal Nature Reviews. The paper said that “Much of the pharmaceutical industry's R&D is now based on the idea that high-affinity binding to a single biological target linked to a disease will lead to medical benefit in humans. Indeed, drug-like small molecules tend to bind promiscuously, and this sometimes turns out to have an important role in their efficacy as well as their so-called off-target effects. Targets are parts of complex networks leading to unpredictable effects, and biological systems show a high degree of redundancy, which could blunt the effects of highly targeted drugs (3).”
In simple terms, the idea that a drug binds with only one target is wishful thinking. As it turns out, every drug binds with many targets in the body, the desired one, and many others. Binding to the ‘other’ targets usually causes all the unwanted, surprising, side effects.
"If one doesn’t understand the complete biology of disease, aiming at one target requires praying for no collateral damage. Any drug that passes clinical trials under this paradigm is a miracle. But, miracles are rare, and unpredictable. Investors need to demand a change. They need to put an end to the “Single Target’ paradigm. Otherwise, a successful drug with no side effects will continue to remain elusive." - Greg Bennett, CBCD
In summary, the ‘Single Target’ paradigm pursued by the pharmaceutical industry is a failure. There is a growing need for a different approach.
The CBCD invites scientists, and investors interested in discussing such an approach to contact the Center at: info (at) CBCD (dot) net.
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. NIH media availability: Protein linked to increased risk of heart failure and death in older adults2
. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia3
. A new treatment for kidney disease-associated heart failure?4
. Blocking digestive enzymes may reverse shock, stop multiorgan failure5
. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press6
. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures7
. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant8
. The Prevention of Heart Failure9
. Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures10
. Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures11
. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure